Ivana Ritter

Binger Str. 173
Ingelheim Am Rhein, RP 55216, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Effect of nerandomilast on survival in patients with pulmonary fibrosis.

Effect of nerandomilast on survival in patients with pulmonary fibrosis.

Journal: The European respiratory journal

Published: February 13, 2026

Efficacy and safety of nerandomilast in patients with autoimmune disease-related progressive pulmonary fibrosis in the FIBRONEER-ILD trial.

Efficacy and safety of nerandomilast in patients with autoimmune disease-related progressive pulmonary fibrosis in the FIBRONEER-ILD trial.

Journal: Annals of the rheumatic diseases

Published: December 23, 2025

Nerandomilast in progressive pulmonary fibrosis: data from the whole follow-up period of the FIBRONEER-ILD trial.

Nerandomilast in progressive pulmonary fibrosis: data from the whole follow-up period of the FIBRONEER-ILD trial.

Journal: The European respiratory journal

Published: September 10, 2025

Nerandomilast in Patients with Progressive Pulmonary Fibrosis.

Nerandomilast in Patients with Progressive Pulmonary Fibrosis.

Journal: The New England journal of medicine

Published: May 19, 2025

Safety and Tolerability of Nintedanib in Patients with Fibrosing Interstitial Lung Diseases: Post-marketing Data.

Safety and Tolerability of Nintedanib in Patients with Fibrosing Interstitial Lung Diseases: Post-marketing Data.

Journal: Advances in therapy

Published: July 31, 2024

Empagliflozin and serum potassium in heart failure: an analysis from EMPEROR-Pooled.

Empagliflozin and serum potassium in heart failure: an analysis from EMPEROR-Pooled.

Journal: European heart journal

Published: December 02, 2021

Empagliflozin and incidence of events consistent with acute kidney injury: Pooled safety analysis in more than 15 000 individuals.

Empagliflozin and incidence of events consistent with acute kidney injury: Pooled safety analysis in more than 15 000 individuals.

Journal: Diabetes, obesity & metabolism

Published: November 16, 2021

Safety of Empagliflozin in Patients With Type 2 Diabetes and Chronic Kidney Disease: Pooled Analysis of Placebo-Controlled Clinical Trials.

Safety of Empagliflozin in Patients With Type 2 Diabetes and Chronic Kidney Disease: Pooled Analysis of Placebo-Controlled Clinical Trials.

Journal: Diabetes care

Published: September 29, 2021

Kidney Function After Initiation and Discontinuation of Empagliflozin in Patients With Heart Failure With and Without Type 2 Diabetes: Insights From the EMPERIAL Trials.

Kidney Function After Initiation and Discontinuation of Empagliflozin in Patients With Heart Failure With and Without Type 2 Diabetes: Insights From the EMPERIAL Trials.

Journal: Circulation

Published: August 16, 2021

Characterization and implications of the initial estimated glomerular filtration rate 'dip' upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial.

Characterization and implications of the initial estimated glomerular filtration rate 'dip' upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial.

Journal: Kidney international

Published: June 11, 2020

Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes.

Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes.

Journal: European heart journal

Published: June 09, 2020

Showing 1-11 of 11

Last Updated: 09/26/2026